- The Pfizer–BioNTech COVID-19 vaccine, sold
under the
brand name
Comirnaty, is an mRNA-based COVID-19
vaccine developed by the
German biotechnology company...
- name
Comirnaty, is an mRNA
vaccine produced by the
German company BioNTech and the
American company Pfizer. In Hong Kong, Macau, and Taiwan,
Comirnaty is...
- Kingdom, 138,000
people had
received the Pfizer-BioNTech COVID‑19
vaccine Comirnaty by 16 December,
during the
first w**** of the UK
vaccination programme...
-
field of
infectious diseases, BioNTech,
partnering with Pfizer,
developed Comirnaty, the
first approved mRNA-based vaccine,
which was
widely used
during the...
- do not
jeopardize the
quality and
integrity of the data from the main
Comirnaty trial and have no
impact on the benefit-risk ****essment or on the conclusions...
-
Advisory Group on
Immunisation (ATAGI)
recommended that the
Pfizer vaccine (
Comirnaty) be
preferred over the
AstraZeneca vaccine in
people under the age of...
- is the
first RNAi drug to
receive regulatory approval. The
second is
Comirnaty, the COVID-19 mRNA
vaccine developed by Pfizer/BioNTech that has received...
- for
Pfizer and BioNTech's COVID-19 vaccine,
Comirnaty, and its
nonproprietary name, tozinameran.
Comirnaty was the
first COVID-19
vaccine brand name approved...
- 593–603. doi:10.1016/j.drudis.2020.11.025. PMC 7694556. PMID 33253920. "
Comirnaty and Pfizer-BioNTech COVID-19 Vaccine". FDA.
January 3, 2022. Archived...
- Pfizer–BioNTech COVID-19
vaccine codenamed BNT162b2 (later
branded as
Comirnaty). This
approval enabled the
start of the UK's COVID-19
vaccination programme...
